COMMUNIQUÉS West-GlobeNewswire

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
14/04/2026
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in [...]
Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model
14/04/2026
Phase 2 Clinical Program Underway as Award-Winning Data Strengthen MTX-001’s Position in a Multi-Billion-Dollar Wound Care Market iFyber Partnership Integrates Advanced Tissue Models and Quantitative Bioanalytics to [...]
Haystack Health Appoints Digital Health Leader Bill Snyder as Chief Executive Officer
14/04/2026
Healthcare executive and founder brings deep experience in value-based care and digital health to accelerate Haystack’s mission of expanding clinical trial access and combating the rising cost of specialty medications [...]
Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes
14/04/2026
Not for distribution to U.S. news wire services or dissemination in the United States. MARKHAM, Ontario, April 14, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“ Extendicare ” or the “ Company ”) (TSX: EXE) announced [...]
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
14/04/2026
On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity CRB-913 [...]
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
14/04/2026
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW). The exclusive event will feature [...]
Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study
14/04/2026
Enhancing emergency triage imaging with Nanox.ARC to improve efficiency and lower radiation dose Collaboration expands clinical evidence base of Nanox.ARC to support broader adoption PETACH TIKVA, Israel, April 14, 2026 [...]
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
14/04/2026
Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth
14/04/2026
Industry veteran Mike Stapleton joins the Board as company enters its next phase of growth SAN FRANCISCO, CALIFORNIA, UNITED STATES, April 14, 2026 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected [...]
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
14/04/2026
CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first [...]
Greenwich LifeSciences Provides Update on Financing Strategy
14/04/2026
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
14/04/2026
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14/04/2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
14/04/2026
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026 QUVIVIQ® is approved through Taiwan’s Streamlined Review [...]
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
14/04/2026
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized [...]
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique
14/04/2026
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat médicament, PTI5803, [...]
PannTheraPi Announces Significant Clinical Development and Strategic Milestones
14/04/2026
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and severe form of epilepsy PannTheraPi secures European patent covering [...]
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
14/04/2026
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare Novo Nordisk will integrate OpenAI's most advanced AI capabilities globally [...]
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
14/04/2026
MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors CAMBRIDGE, United Kingdom, April 14, 2026 (GLOBE [...]

Pages